Hemocompatibility and Long‐Term Outcomes in <scp>H</scp> eart <scp>W</scp> are Versus <scp>H</scp> eart <scp>M</scp> ate <scp>II</scp> Versus <scp>H</scp> eart <scp>M</scp> ate 3: Multicenter Real‐World Cohort
In this real-world, multicenter cohort, HM3 was associated with better overall survival and a lower thromboembolic burden than HMII and HVAD, while bleeding risk remained similar. These findings support preferential selection of HM3 when device choice is feasible, and emphasize the need for targeted strategies to mitigate hemostatic complications across all LVADs.
Authors
- A. Haneya
- O. Allham
- Yusuf Shieba (ORCID: https://orcid.org/0000-0002-0565-7795)
- Rashad Zayat (ORCID: https://orcid.org/0000-0003-2243-8743)
- Lachmandath Tewarie
- Alish Kolashov (ORCID: https://orcid.org/0009-0000-2048-1049)
- Ahmed F. A. Mohammed
- Ajay Moza (ORCID: https://orcid.org/0009-0009-9330-142X)
- Bernd Panholzer
- Hamza H. H. Ben Nasir
Institutions
- South Valley University (EG)
- Krankenhaus der Barmherzigen Brüder Trier (DE)
- University Hospital Schleswig-Holstein (DE)
- Klinikum Links der Weser (DE)
- Technische Universität Dresden (DE)
- RWTH Aachen University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Artificial Organs
- Published
- 2026-01-04
- DOI
- https://doi.org/10.1111/aor.70086
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00